» Articles » PMID: 29270166

Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1

Abstract

In humans, recessive loss-of-function mutations in are associated with mycobacterial and viral infections, whereas gain-of-function (GOF) mutations in are associated with a type of primary immunodeficiency related mainly, but not exclusively, to chronic mucocutaneous candidiasis (CMC). We studied and established a molecular diagnosis in a pediatric patient with mycobacterial infections, associated with CMC. The patient, daughter of a non-consanguineous mestizo Mexican family, had axillary adenitis secondary to BCG vaccination and was cured with resection of the abscess at 1-year old. At the age of 4 years, she had a supraclavicular abscess with acid-fast-staining bacilli identified in the soft tissue and bone, with clinical signs of disseminated infection and a positive Gene-X-pert test, which responded to anti-mycobacterial drugs. Laboratory tests of the IL-12/interferon gamma (IFN-γ) circuit showed a higher production of IL-12p70 in the whole blood from the patient compared to healthy controls, when stimulated with BCG and BCG + IFN-γ. The whole blood of the patient produced 35% less IFN-γ compared to controls assessed by ELISA and flow cytometry, but IL-17 producing T cells from patient were almost absent in PBMC stimulated with PMA plus ionomycin. Signal transduction and activator of transcription 1 (STAT1) was hyperphosphorylated at tyrosine 701 in response to IFN-γ and -α, as demonstrated by flow cytometry and Western blotting in fresh blood mononuclear cells and in Epstein-Barr virus lymphoblastoid cell lines (EBV-LCLs); phosphorylation of STAT1 in EBV-LCLs from the patient was resistant to inhibition by staurosporine but sensitive to ruxolitinib, a Jak phosphorylation inhibitor. Genomic DNA sequencing showed a mutation in in cells from the patient, absent in her parents and brother; a known T385M missense mutation in the DNA-binding domain of the transcription factor was identified, and it is a GOF mutation. Therefore, GOF mutations in can induce susceptibility not only to fungal but also to mycobacterial infections by mechanisms to be determined.

Citing Articles

Immunophenotyping and Therapeutic Insights from Chronic Mucocutaneous Candidiasis Cases with STAT1 Gain-of-Function Mutations.

Lei W, Lo Y, Tsumura M, Ding J, Lo C, Lin Y J Clin Immunol. 2024; 44(8):184.

PMID: 39177867 DOI: 10.1007/s10875-024-01776-9.


Leveraging Systems Immunology to Optimize Diagnosis and Treatment of Inborn Errors of Immunity.

Mauracher A, Henrickson S Front Syst Biol. 2023; 2.

PMID: 37670772 PMC: 10477056. DOI: 10.3389/fsysb.2022.910243.


Cutaneous tuberculosis in the pediatric population: A review.

Maloney M, Cohen B JAAD Int. 2023; 12:105-111.

PMID: 37404246 PMC: 10315778. DOI: 10.1016/j.jdin.2023.05.001.


Identification of Hub Genes Associated with Diabetes Mellitus and Tuberculosis Using Bioinformatic Analysis.

Liu S, Ren W, Yu J, Li C, Tang S Int J Gen Med. 2021; 14:4061-4072.

PMID: 34354368 PMC: 8331204. DOI: 10.2147/IJGM.S318071.


Chronic demodicosis in patients with immune dysregulation: An unexpected infectious manifestation of Signal transducer and activator of transcription (STAT)1 gain-of-function.

Shamriz O, Lev A, Simon A, Barel O, Javasky E, Matza-Porges S Clin Exp Immunol. 2021; 206(1):56-67.

PMID: 34114647 PMC: 8446414. DOI: 10.1111/cei.13636.


References
1.
Yamazaki Y, Yamada M, Kawai T, Morio T, Onodera M, Ueki M . Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol. 2014; 193(10):4880-7. DOI: 10.4049/jimmunol.1401467. View

2.
Caragol I, Raspall M, Fieschi C, Feinberg J, Larrosa M, Hernandez M . Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin Infect Dis. 2003; 37(2):302-6. DOI: 10.1086/375587. View

3.
Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Becerra J . Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016; 127(25):3154-64. PMC: 4920021. DOI: 10.1182/blood-2015-11-679902. View

4.
Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

5.
Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen I, Al-Jumaah S . Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003; 33(3):388-91. DOI: 10.1038/ng1097. View